Breaking News

Roche’s MabThera Launch Triggers $5M Halozyme Milestone

June 25, 2014

Marks second product to use Halozyme's Enhanze technology

Roche’s MabThera SC has launched in Europe, triggering a $5 million milestone payment to Halozyme Therapeutics under the companies’ license and collaboration agreement. In addition to Herceptin SC, MabThera SC is the second subcutaneous formulation of one of Roche's oncology products to use Halozyme's Enhanze (recombinant human hyaluronidase) technology.
 
MabThera SC is approved for the treatment of patients with follicular lymphoma and diffuse large B-cell lymphoma. This formulation could potentially save time for patients, physicians and health care providers.

blog comments powered by Disqus
  • The Western API Industry

    The Western API Industry

    Dr. Enrico T. Polastro, Arthur D. Little||January 28, 2016
    Temporary reprieve or lasting recovery?

  • A Look at DCAT Week ‘16

    Tim Wright, Editor||January 28, 2016
    On the pulse of the pharmaceutical manufacturing value chain, DCAT Week ‘16 will deliver top-flight education programs and networking events.

  • Manufacturing Sterile Injectables

    Manufacturing Sterile Injectables

    Colin MacKay, Symbiosis Pharmaceutical Services||November 17, 2015
    Are quality standards too high in the manufacture of injectables?